SCHEMBL30148436

SCHEMBL30148436

CC(C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)O)C(C)C)C(C)C)C(C)C

nearest known ligand 0.53

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ MAGI3 Q5TCQ9 1/20 0.53
▸ IL23R Q5VWK5 10/20 0.51
▸ KISS1R Q969F8 3/20 0.51
▸ CTSC P53634 1/20 0.50
▸ SIRT5 Q9NXA8 1/20 0.48
▸ GHSR Q92847 1/20 0.48
▸ CTSB P07858 1/20 0.48
▸ CTSK P43235 1/20 0.48
▸ ACE P12821 1/20 0.48
▸ MC4R P32245 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30305641 1.00 MAGI3 (0.53) MAGI3IL23RKISS1RCTSCSIRT5
SCHEMBL30945413 1.00 MAGI3 (0.53) MAGI3IL23RKISS1RCTSCSIRT5
SCHEMBL31065007 0.98 MAGI3 (0.52) MAGI3IL23RKISS1RCTSCGHSR
SCHEMBL30093039 0.97 IL23R (0.51) MAGI3IL23RKISS1RCTSCSIRT5
SCHEMBL30093123 0.97 IL23R (0.51) MAGI3IL23RKISS1RCTSCSIRT5
SCHEMBL30339793 0.97 IL23R (0.51) MAGI3IL23RKISS1RCTSCSIRT5
SCHEMBL30302924 0.97 IL23R (0.51) MAGI3IL23RKISS1RCTSCSIRT5
SCHEMBL30302936 0.97 IL23R (0.51) MAGI3IL23RKISS1RCTSCSIRT5
SCHEMBL29799990 0.97 IL23R (0.51) MAGI3IL23RKISS1RCTSCSIRT5
SCHEMBL30305362 0.97 IL23R (0.51) MAGI3IL23RKISS1RCTSCSIRT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023044487-A1 TREATMENT OF LUNG DISEASE OR INJURY USING ENGINEERED ANTIMICROBIAL PEPTIDES PEPTILOGICS, INC. (US) 2023-03-23 — — WO claimed
US-20250320266-A1 Methods and Compositions for Treatment of Antibiotic-Resistant Bacterial Infections UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) 2025-10-16 — — US disclosed
US-20250277002-A1 ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE PEPTILOGICS, INC. 2025-09-04 — — US disclosed
US-12371463-B2 Methods and compositions for treatment of antibiotic-resistant bacterial infections University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2025-07-29 — — US disclosed
EP-4401752-A1 ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF Peptilogics, Inc. (US) 2024-07-24 — — EP disclosed
US-20230107222-A1 ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE PEPTILOGICS, INC. 2023-04-06 — — US disclosed
WO-2023044423-A1 ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF PEPTILOGICS, INC. (US) 2023-03-23 — — WO disclosed
US-20220332777-A1 Methods and Compositions for Treatment of Antibiotic-Resistant Bacterial Infections UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2022-10-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250277002-A1 ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE NGLY1, PRF1, LNPEP MAGI3 3116/4885IL23R 2492/4885KISS1R 3536/4885
US-20230107222-A1 ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE NGLY1, PRF1, LNPEP MAGI3 3116/4885IL23R 2492/4885KISS1R 3536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback